Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.76 |
| ▸ | HTR3A | P46098 | 1/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | HTR1D | P28221 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2166919 | 0.87 | HRH4 (0.85) | HRH4HTR3AHTR1AADRA2AADRA2C | |
| SCHEMBL2167865 | 0.86 | HRH4 (1.00) | HRH4HTR3AHTR1AADRA2AADRA2C | |
| SCHEMBL2168359 | 0.86 | HRH4 (0.74) | HRH4HTR3AHTR1AADRA2AADRA2C | |
| SCHEMBL605878 | 0.86 | HRH4 (0.74) | HRH4HTR3AHTR1AADRA2AADRA2C | |
| SCHEMBL2169559 | 0.86 | HRH4 (0.74) | HRH4HTR3AHTR1AADRA2AADRA2C | |
| Hydrochloric Acid SCHEMBL603952 | 0.86 | HRH4 (0.82) | HRH4HTR3AHTR1AADRA2AADRA2C | |
| SCHEMBL2166821 | 0.85 | HRH4 (0.82) | HRH4HTR3AHTR1AADRA2AADRA2C | |
| SCHEMBL2166566 | 0.84 | HRH4 (0.94) | HRH4HTR3AHTR1AADRA2AADRA2C | |
| SCHEMBL604950 | 0.84 | HRH4 (0.70) | HRH4HTR3AHTR1AADRA2AADRA2C | |
| SCHEMBL2166625 | 0.84 | HRH4 (0.76) | HRH4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985745-B2 | Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080194538-A1 | Method for Pain Treatment | ABBVIE INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008060766-A2 | HISTAMINE H4 RECEPTOR LIGANDS FOR USE IN PAIN TREATMENT | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194538-A1 | Method for Pain Treatment | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3A 86/4885HTR1A 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.